A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer

BACKGROUND: Patients with chemotherapy refractory metastatic colorectal cancer (CRC) have a poor prognosis and limited therapeutic options. In this phase Ib/II clinical trial, we established the maximum tolerated dose (MTD) and recommended phase II dose (RPTD) for the combination of capecitabine and...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:BMC Cancer
Autori principali: Strickler, John H., Rushing, Christel N., Niedzwiecki, Donna, McLeod, Abigail, Altomare, Ivy, Uronis, Hope E., Hsu, S. David, Zafar, S. Yousuf, Morse, Michael A., Chang, David Z., Wells, James L., Blackwell, Kimberly L., Marcom, P. Kelly, Arrowood, Christy, Bolch, Emily, Haley, Sherri, Rangwala, Fatima A., Hatch, Ace J., Nixon, Andrew B., Hurwitz, Herbert I.
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2019
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6824108/
https://ncbi.nlm.nih.gov/pubmed/31675952
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-6234-8
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi